Q&A: Fujifilm Diosynth’s new CEO Lars Petersen talks priorities and plans for the CDMO

Last week saw a change at the top for the contract manufacturer Fujifilm Diosynth Biotechnologies, with Lars Petersen replacing Martin Meeson as president and CEO.

Petersen has been in the manufacturing business for well over 20 years, working at major manufacturers such as Novo Nordisk, Genentech and Biogen. At Fujifilm, where Petersen has been for the last four years, he most recently served as COO of a manufacturing site in Hillerød, Denmark, and headed up the large-scale strategic business unit.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Congress nears deal to rein in PBMs after years of debate

WASHINGTON — After two years of haggling, Congress has nearly reached a deal to rein in the drug-industry middlemen known as pharmacy benefit managers. Lawmakers

December 17, 2024

Making sense of the debate’s health care debate

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

July 2, 2024

Garlic as a potent weapon against atherosclerosis

Researchers identified garlic’s potential to treat atherosclerosis by regulating ferroptosis and reducing lipid peroxidation, offering a safer alternative to current treatments.

July 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.